Jordana Jampel

DocwireNews

Because treatment options for amyotrophic lateral sclerosis (ALS) are lacking, a phase 2 trial of reldesemtiv aimed to determine whether the drug slows disease progression. The COURAGE-ALS trial was a double-blind, placebo-controlled phase 3 randomized trial conducted across 83 ALS centers in 16 countries between August 2021 and July 2023. Results were <a href="https://jamanetwork.com/journals/jamaneurology/fullarticle/2831901">published</a> in JAMA Neurology.
The first 24-week period included reldesemtiv 300 mg or placebo; all participants received reldesemtiv 300 mg during the second 24-week period, with a 4-week follow-up. Criteria for participant inclusion was definite, probable, or possible ALS with lower motor neuron signs by modified El Escorial Criteria; ALS symptoms for 24 months or less; ALS Functional Rating Scale-Revised (ALSFRS-R) total score of 44 or less; and forced vital capacity greater than or equal to 65% of predicted.
The study included 486 participants (mean age, 59.4 years); 325 were randomly assigned to reldesemtiv, and 161 were randomly assigned to placebo. The second 24-week interim analysis included 256 patients. The mean difference in the ALSFRS-R score from baseline to week 24 was -1.1 (0.53; 95% CI, -2.17 to -0.08; P=0.04), favoring placebo. The win probability was 0.44 for reldesemtiv and 0.49 for placebo, with a win ratio of 0.91 (95% CI, 0.77-1.10; P=0.11).
Given the significant amount of missing data due to early termination, a combined assessment was prioritized, but this also failed to demonstrate a benefit from reldesemtiv. “In the COURAGE-ALS randomized clinical trial, the overall development of FSTAs evaluated an important clinical hypothesis with great rigor. The results, although not supportive of future development for ALS, are clear and important,” the researchers concluded.
Reference
Shefner JM, Cudkowicz ME, Genge A, et al. Reldesemtiv in amyotrophic lateral sclerosis: results from the COURAGE-ALS randomized clinical trial. JAMA Neurol. Published online March 24, 2025. doi:10.1001/jamaneurol.2025.0241

Because treatment options for amyotrophic lateral sclerosis (ALS) are lacking, a phase 2 trial of reldesemtiv aimed to determine whether the drug slows disease progression. The COURAGE-ALS trial was a double-blind, placebo-controlled phase 3 randomized trial conducted across 83 ALS centers in 16 countries between August 2021 and July 2023. Results were <a href="https://jamanetwork.com/journals/jamaneurology/fullarticle/2831901">published</a> in JAMA Neurology.The first 24-week period included reldesemtiv 300 mg or placebo; all participants received reldesemtiv 300 mg during the second 24-week period, with a 4-week follow-up. Criteria for participant inclusion was definite, probable, or possible ALS with lower motor neuron signs by modified El Escorial Criteria; ALS symptoms for 24 months or less; ALS Functional Rating Scale-Revised (ALSFRS-R) total score of 44 or less; and forced vital capacity greater than or equal to 65% of predicted.The study included 486 participants (mean age, 59.4 years); 325 were randomly assigned to reldesemtiv, and 161 were randomly assigned to placebo. The second 24-week interim analysis included 256 patients. The mean difference in the ALSFRS-R score from baseline to week 24 was -1.1 (0.53; 95% CI, -2.17 to -0.08; P=0.04), favoring placebo. The win probability was 0.44 for reldesemtiv and 0.49 for placebo, with a win ratio of 0.91 (95% CI, 0.77-1.10; P=0.11).Given the significant amount of missing data due to early termination, a combined assessment was prioritized, but this also failed to demonstrate a benefit from reldesemtiv. “In the COURAGE-ALS randomized clinical trial, the overall development of FSTAs evaluated an important clinical hypothesis with great rigor. The results, although not supportive of future development for ALS, are clear and important,” the researchers concluded.ReferenceShefner JM, Cudkowicz ME, Genge A, et al. Reldesemtiv in amyotrophic lateral sclerosis: results from the COURAGE-ALS randomized clinical trial. JAMA Neurol. Published online March 24, 2025. doi:10.1001/jamaneurol.2025.0241

David M. Waterhouse, MD, MPH

Clinical Trial Gaps in TNBC: New Data Underscores Access Inequities for Black Women

Triple-Negative Breast Cancer

Sibylle Loibl, MD

How DESTINY-Breast09 Could Reshape HER2+ mBC Care: Insights From Dr. Sibylle Loibl

HER2 Breast Cancer

Central Obesity Strongly Associated With Psoriasis Risk

Psoriasis

Latest News

ALS Therapy Trial Fails to Benefit Patients Over Placebo

Neurology

ALS Functional Rating Scale-Revised results scores were used to determined therapeutic efficacy versus placebo. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe